A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, INVESTIGATOR- AND PARTICIPANT-BLINDED PHASE 2A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DFV890 AND MAS825 FOR INFLAMMATORY MARKER REDUCTION IN AN ADULT POPULATION WITH CORONARY HEART DISEASE AND CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP)
- Registry ID
- CADPT15A12201
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2024-02-12
- Completion date
- 2024-10-29
- Last update
- 2023-12-04
Conditions
- CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE
Related clinical trials
- A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, INVESTIGATOR- AND PARTICIPANT-BLINDED PHASE 2A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DFV890 FOR INFLAMMATORY MARKER REDUCTION IN ADULT PARTICIPANTS WITH CORONARY HEART DISEASE AND ELEVATED HSCRP
- A PROSPECTIVE, COMPARATIVE, RANDOMIZED, MULTI-CENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY OF THE SAFETY AND EFFICACY OF CMX-2043 FOR PERIPROCEDURAL INJURY PROTECTION IN SUBJECTS UNDERGOING CORONARY ANGIOGRAPHY AT RISK OF RADIO-CONTRAST INDUCED NEPHROPATHY (CARIN)
- ELIMINATE CORONARY HEART DISEASE
View on source registry